FATP2 Monoclonal antibody, PBS Only (Capture)
FATP2 Monoclonal Antibody for WB, IHC, IF/ICC, Cytometric bead array, Indirect ELISA
Host / Isotype
Mouse / IgG1
Reactivity
human, rat
Applications
WB, IHC, IF/ICC, Cytometric bead array, Indirect ELISA
Conjugate
Unconjugated
CloneNo.
2C10D7
Cat no : 68074-1-PBS
Synonyms
Validation Data Gallery
Tested Applications
Recommended dilution
Application | Dilution |
---|---|
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. |
Product Information
68074-1-PBS targets FATP2 as part of a matched antibody pair:
MP50832-1: 68074-1-PBS capture and 68074-2-PBS detection (validated in Cytometric bead array)
Unconjugated mouse monoclonal antibody pair in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation.
This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.
Tested Reactivity | human, rat |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Immunogen | FATP2 fusion protein Ag5390 相同性解析による交差性が予測される生物種 |
Full Name | solute carrier family 27 (fatty acid transporter), member 2 |
Calculated molecular weight | 567 aa, 65 kDa |
Observed molecular weight | 70 kDa |
GenBank accession number | BC057770 |
Gene symbol | FATP2/SLC27A2 |
Gene ID (NCBI) | 11001 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS Only |
Storage Conditions | Store at -80°C. |
Background Information
FATP2 is a member of the FATP family which functions in lipid and bile metabolism. It is a 70-kDa protein predominantly expressed in liver and kidney. Kidney FATP2 is localized exclusively to proximal tubule epithelial cells along the apical but not the basolateral membrane, and regulates lipoapoptosis. FATP2 is involved in metabolism-related diseases including nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), and is a potential clinical biomarker and therapeutic target.